Dianthus Therapeutics vs Upstream Bio
DNTH and UPB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DNTH and UPB compare
Dianthus Therapeutics is the larger company, worth 28 times as much as Upstream Bio ($5.0B against $175M).
Upstream Bio scores higher on the StockData Score (8 against 7 for Dianthus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DNTH | UPB |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $175M |
| Share price | $89.30 | $3.20 |
| Change, 1 year | 144% | −86.4% |
| Change, 5 years | −16.6% | – |
| Beta (5Y) | 1.44 | 1.35 |
| Employees | 92 | 75 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 61.1× |
| P/B | 4.0× | 0.7× (better) |
| Growth | ||
| Revenue growth (TTM) | – | 2.5% |
| Profitability | ||
| Operating margin | – | −6116% |
| Net margin | – | −5712% |
| Return on equity | −22.6% (better) | −53.5% |
| Return on invested capital | −22.2% (better) | −846% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 30.02 (better) | 20.45 |
| Altman Z-score | 85.71 (better) | 4.95 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | −0.01% | – |
| Shareholder yield | −0.01% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 118% | 92.3% |
| Held by insiders | 9.1% | 8.6% |
| Insider net buying, 12 months | −$63.8M | −$105K (better) |
| Short interest, % of float | 18.2% | 7.1% |
Go deeper
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
- UPB stock overview
- UPB income statement
- UPB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.